Zacks Research Issues Negative Outlook for Omnicell Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Investment analysts at Zacks Research lowered their Q2 2025 earnings estimates for shares of Omnicell in a note issued to investors on Wednesday, June 18th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.10 for the quarter, down from their previous estimate of $0.12. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.16 EPS, FY2025 earnings at $0.28 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.22 EPS, FY2026 earnings at $0.44 EPS, Q1 2027 earnings at ($0.03) EPS and FY2027 earnings at $0.88 EPS.

OMCL has been the subject of a number of other research reports. Piper Sandler reiterated an “overweight” rating on shares of Omnicell in a report on Friday, May 23rd. Wells Fargo & Company reiterated an “overweight” rating and issued a $37.00 price target (up previously from $35.00) on shares of Omnicell in a report on Friday, May 23rd. Benchmark cut their price target on shares of Omnicell from $62.00 to $40.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. Bank of America increased their price target on shares of Omnicell from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, May 23rd. Finally, JPMorgan Chase & Co. dropped their target price on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, March 20th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $44.83.

Omnicell Stock Performance

Shares of OMCL opened at $29.10 on Monday. The company has a 50-day simple moving average of $29.34 and a 200-day simple moving average of $36.12. The company has a quick ratio of 1.23, a current ratio of 1.38 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $1.36 billion, a PE ratio of 63.26 and a beta of 0.78. Omnicell has a 52-week low of $22.66 and a 52-week high of $55.75.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.10. The business had revenue of $269.67 million during the quarter, compared to the consensus estimate of $260.18 million. Omnicell had a net margin of 1.87% and a return on equity of 4.60%. The business’s revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.03 EPS.

Hedge Funds Weigh In On Omnicell

Several hedge funds have recently added to or reduced their stakes in OMCL. Van ECK Associates Corp increased its holdings in Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after acquiring an additional 315 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of Omnicell by 4.0% during the fourth quarter. Principal Financial Group Inc. now owns 238,356 shares of the company’s stock worth $10,612,000 after buying an additional 9,267 shares in the last quarter. CIBC Asset Management Inc purchased a new stake in shares of Omnicell during the fourth quarter worth about $201,000. First Horizon Advisors Inc. grew its holdings in shares of Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after buying an additional 355 shares in the last quarter. Finally, Illinois Municipal Retirement Fund purchased a new stake in shares of Omnicell during the fourth quarter worth about $1,073,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.